The Latest Cardiac and Vascular News
NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. “We […]
XPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure — Significantly Reduced Hypertrophy in Patients with Hypertrophic Cardiomyopathy BRISBANE, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) announced results from its cardiac magnetic resonance imaging (CMR) substudy of mavacamten for the potential treatment of hypertrophic […]
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with Markers of HCM Severity in Non-Obstructive HCM Non-Clinical Data Show Mavacamten Surrogate Preserved Cardiac Function in Disease Model, Slowing Progression BRISBANE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today presented clinical and non-clinical data related to […]
Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages […]
Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020 BRISBANE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020. Recent Clinical Program Highlights Mavacamten for Hypertrophic Cardiomyopathy (HCM) EXPLORER-HCM Data Presented at the European Society of Cardiology 2020 […]
BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded to help advance MyoKardia’s mission […]
NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price […]
Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise Expected to be Accretive to Non-GAAP Earnings […]
Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) and LianBio announced today that they have entered […]
BRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020. “The second quarter of 2020 was one of incredible progress across our R&D pipeline, including the exciting new data from our danicamtiv program highlighting its unique ability to directly activate both […]
